Brivudin (bromovinyl deoxyuridine)

Area of Science:

• Virology
• Pharmacology
• Dermatology

Background:

• Herpes zoster, caused by varicella zoster virus (VZV), requires early treatment in immunocompetent adults.
• Antiviral therapies aim to inhibit VZV replication and alleviate symptoms.
• Post-herpetic neuralgia (PHN) is a significant complication, particularly in older patients.

Purpose of the Study:

• To evaluate the efficacy and tolerability of oral brivudin in treating acute herpes zoster.
• To compare brivudin with standard antiviral treatments like acyclovir and famciclovir.
• To assess the impact of brivudin on the incidence of post-herpetic neuralgia.

Main Methods:

• Phase III clinical trials involving immunocompetent patients with herpes zoster.
• Comparison of once-daily brivudin (125mg) against oral acyclovir (800mg five times daily) and oral famciclovir (250mg three times daily).
• Assessment of key endpoints including time to last vesicular eruption, lesion healing, pain alleviation, and prevalence of PHN.

Main Results:

• Brivudin significantly reduced the time to last vesicular eruption compared to acyclovir.
• Brivudin demonstrated comparable efficacy to acyclovir in lesion healing and pain relief.
• A significantly lower incidence of PHN was observed with brivudin versus acyclovir in patients aged 50 years and older.
• Brivudin showed similar efficacy to famciclovir regarding PHN prevalence, healing time, and lesion healing.

Conclusions:

• Oral brivudin is an effective and well-tolerated early treatment option for acute herpes zoster in immunocompetent adults.
• Brivudin offers advantages over acyclovir in reducing healing time and PHN risk.
• Brivudin presents a comparable efficacy profile to famciclovir for herpes zoster treatment.